A multicenter phase-three study in 1019 patients with type 1 or type 2 diabetes and DPN assessed the effects of recombinant NGF (rhNGF) 0.1 mcg/kg (n = 504) or placebo (n = 515) subcutaneously three times per week over 48 weeks [41]. The gene discussed is NGF; the disease is type 2 diabetes mellitus.